Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1

Haematologica

Volumn 95, Issue 5, 2010, Pages 696-698

  Bain, Barbara J ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DASATINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; MIDOSTAURIN; NILOTINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB;

3' UNTRANSLATED REGION; EDITORIAL; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; FUSION GENE; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE REARRANGEMENT; GENE TARGETING; GENETIC HETEROGENEITY; GENOTYPE; HUMAN; IMMUNOPHENOTYPING; LYMPHOBLASTOMA; MYELOID LEUKEMIA; POINT MUTATION;

EOSINOPHILIA; HEMATOLOGIC NEOPLASMS; HUMANS; LYMPHOMA; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 77952298360     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.021675     Document Type: Editorial

References (23)

1. Bain BJ, Gilliland DG, Horny H-P, Vardiman JW. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB and FGFR1. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J and Vardiman JW (eds) World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissue, 4th edn. 2008 IARC Press, Lyon, pp. 68-73.
2. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21(6):1183-8.
3. Michaux L, Mecucci C, Velloso ERP, Dierlamm J, Cries A, Louwagie A, et al. About the t(8;13)(p11;q12) clinico-pathologic entity. Blood. 1996;87(4):1658-9.
4. Still IH, Chernova O, Hurd D, Stone RM, Cowell JK. Molecular characterization of the t(8;13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11. Blood. 1997;90(8):3136-41.
5. Al-Obaidi MJ, Rymes N, White P, Pomfret M, Smith H, Starcznski J, Johnson R. A fourth case of 8p11 myeloproliferative disorder transforming to B-lineage acute lymphoblastic leukaemia. A case report. Acta Haematol. 2002;107(2):98-101.
6. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-14.
7. Tashiro H, Shirasaki R, Noguchi M, Gotoh M, Kawasugi K, Shirafuji N. Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. Int J Hematol. 2006; 83(5):433-8.
8. Bain BJ. Leukaemia Diagnosis, 4th edn, Wiley-Blackwell, Oxford, 2010.
9. Erben P, Gosenca D, Müller MC, Reinhard J, Score J, del Valle F, et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica. 2010;95(5):738-44.
10. Elling C, Erben P, Walz C, Frickenhaus M, Schemionek M, Stehling M, et al. Novel PDGFRA point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia in vitro and in vivo. Blood. 2009:114:319.
11. Sorour Y, Dalley CD, Snowden JA, Cross NC, Reilly JT. Acute myeloid leukaemia with associated eosinophilia: justification for FIP1L1-PDGFRA screening in cases lacking the CBFB-MYH11 fusion gene. Br J Haematol. 2009;146(2):225-7.
12. Jovanovic JV, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia. Blood. 2007;109(11):4635-40.
13. Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRa T674I eosinophilic leukemia with single agent sorafenib. Leukemia. 2009;23(5):845-51.
14. Von Bubnoff N, Gorantla SP, Engh RA, de Oliveira T, Thoene S, Åberg E, et al. Sorafenib and nilotinib are candidates to overcome imatinib resistance in myeloproliferation with FIP1L1-PDGFRA. Blood. 2009: 114:1138.
15. Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, et al. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Allergy. 2009;64(6):913-8.
16. Hidalgo-Curtis C, Apperley JF, Stark A, Jeng M, Gotlib J, Chase A, et al. Fusion of PDGFRB to two distinct loci as 3p21 and a third as 12q13 in imatinib-responsive myeloproliferative neoplasms. Br J Haematol. 2010; 148(2): 268-73.
17. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, et al. Durable responses to imatinib in patients with PDGRB fusion genepositive and BCR-ABL-negative myeloproliferative disorders. Blood. 2007;109(1): 61-4.
18. Lierman E, Lahortiga I, Van Miegroet H, Mentens N, Marynen P, Cools J. The ability of sorafenib to inhibit oncogenic PDGFRb and FLT3 mutants and overcome resistance to other small molecule inhibitors. Haematologica. 2007:92(1):27-34.
19. Soler G, Nusbaum S, Varet B, Macintyre EA, Vekemans M, Romana SP, et al. LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome. Leukemia. 2009;23(7):1359-61.
20. Hidalgo-Curtis C, Chase A, Drachenberg M, Roberts MW, Finkelstein JZ, Mould S, et al. The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1. Genes Chromosomes Cancer. 2008;47(5):379-85.
21. Lourenço GJ, Ortega MM, Freitas LLL, Borgnone RAV, Fattori A, Lorand-Metze I, et al. The rare t(6;8)(q27;p11) translocation in a case of chronic myeloid neoplasm mimicking polycythaemia vera. Leuk Lymphoma. 2008;49(9):1832-5.
22. Chen J, DeAngelo DJ, Kutok JL, Williams IR, Lee BH, Wadleigh M, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci. USA 2004;101(40): 14479-84.
23. Chase A, Grand FH, Cross NC. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood. 2007;110(10): 3729-34.